Prolia as Osteoporosis Treatment for Post-Menopausal Women
by Clinton Gil in Fitness on Oct 17, 2010
The United States Food and Drug Administration (FDA) have approved the use of the drug Prolia as a treatment to prevent bone fracture caused by osteoporosis in post-menopausal women. After all, based on statistics released by the U.S. government, women consist around 80 percent of individuals with osteoporosis. In addition, half of the women whose ages are 50 and above are sure to sustain fractures that are related to osteoporosis at some time in their lives.
According to news released by the FDA, Prolia, also known as denosumab, is an injectable drug that is given every six months to strengthen the bone, increase its mass and prevent its destruction. The evaluation of Prolia involved the clinical trials of more than 7,800 women whose ages ranged from 60 to 91.
However, Prolia has been reported to have the following common side-effects: Pain in the extremities and back, infection in the bladder, and heightened cholesterol. Some severe reactions have included some skin reactions, low calcium in the blood, and osteonecrosis of the jaw. The latter reaction occurs mainly because Prolia suppresses the turnover of bone. Thus, according to the FDA, Prolia, manufactured by the Amgen Inc. from Thousand Oaks, California, will be sold accompanied by a medical guide explaining the risk to the patient.
Related Posts:
